Related references
Note: Only part of the references are listed.Dynamic changes in circulating PD-1+CD8+T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer
Chang Gon Kim et al.
EUROPEAN JOURNAL OF CANCER (2021)
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Meng Qiao et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
Jean-Christophe Beltra et al.
IMMUNITY (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors (vol 25, pg 2144, 2019)
Kyung Hwan Kim et al.
CLINICAL CANCER RESEARCH (2020)
Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer
Hong Tao et al.
LUNG CANCER (2020)
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
Deborah B. Doroshow et al.
CLINICAL CANCER RESEARCH (2019)
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
C. G. Kim et al.
ANNALS OF ONCOLOGY (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer
Shaun M. O'Brien et al.
CANCER IMMUNOLOGY RESEARCH (2019)
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
Francesca Alfei et al.
NATURE (2019)
TOX is a critical regulator of tumour-specific T cell differentiation
Andrew C. Scott et al.
NATURE (2019)
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Omar Khan et al.
NATURE (2019)
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers
Chang Gon Kim et al.
SCIENCE IMMUNOLOGY (2019)
Defining 'T cell exhaustion'
Christian U. Blank et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Biomarker strategy in lung cancer
Mine Esencay et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer
Nicholas M. Mark et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Brandon W. Higgs et al.
CLINICAL CANCER RESEARCH (2018)
The prognostic effect of the epidermal growth factor receptor gene mutation on recurrence dynamics of lung adenocarcinoma
In Kyu Park et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2018)
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Daniela S. Thommen et al.
NATURE MEDICINE (2018)
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
Xinyi Guo et al.
NATURE MEDICINE (2018)
The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Thomas Duhen et al.
NATURE COMMUNICATIONS (2018)
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
Roger Sun et al.
LANCET ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Proliferation of PD-1+CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients
Alice O. Kamphorst et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway
Yasminka Jakubek et al.
CANCER RESEARCH (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Genetic and Epigenetic Regulation of PD-1 Expression
Alexander P. R. Bally et al.
JOURNAL OF IMMUNOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer A Review
Adrian G. Sacher et al.
JAMA ONCOLOGY (2016)
Regulatory circuits of T cell function in cancer
Daniel E. Speiser et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project
Fiona H. Blackhall et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non-Small-Cell Lung Cancer
Young Tae Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma
Takayuki Kosaka et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Share Paper
